Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxane-induced glaucoma.

E Fabre-Guillevin, N Tchen, M F Anibali-Charpiat

    Lancet (London, England)
    |October 8, 1999
    PubMed
    Summary
    This summary is machine-generated.

    Doxetaxel chemotherapy for breast cancer can cause glaucoma. This eye condition reappeared when the patient was later treated with paclitaxel, another chemotherapy drug.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Checkpoint inhibitors in metastatic papillary renal cell carcinoma.

    Cancer treatment reviews·2021
    Same author

    Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.

    Asia-Pacific journal of clinical oncology·2020
    Same author

    EPOCK study protocol: a mixed-methods research program evaluating cancer care coordination nursing occupations in France as a complex intervention.

    BMC health services research·2019
    Same author

    Asymptomatic stroke is an underestimated side effect of cabozantinib.

    Revue neurologique·2019
    Same journal

    Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

    Lancet (London, England)·2026
    Same journal

    Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

    Lancet (London, England)·2026
    Same journal

    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

    Lancet (London, England)·2026
    Same journal

    The US Ebola response and the future of global health leadership.

    Lancet (London, England)·2026
    Same journal

    Daniel Mason: a tale of change.

    Lancet (London, England)·2026
    Same journal

    The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

    Lancet (London, England)·2026
    See all related articles

    Area of Science:

    • Ophthalmology
    • Medical Oncology

    Background:

    • Metastatic breast cancer treatment often involves chemotherapy.
    • Doxetaxel and paclitaxel are common chemotherapeutic agents used in breast cancer management.

    Observation:

    • A patient undergoing doxetaxel therapy for metastatic breast cancer developed glaucoma.
    • The glaucoma symptoms reappeared during subsequent treatment with paclitaxel.

    Findings:

    • Chemotherapy-induced glaucoma is a potential adverse effect.
    • Both doxetaxel and paclitaxel may be associated with the development or recurrence of glaucoma.

    Implications:

    • Ophthalmologists and oncologists should be aware of the risk of glaucoma with these chemotherapies.
    • Careful ophthalmic monitoring is crucial for patients receiving doxetaxel or paclitaxel.
  • This case highlights the need for vigilance regarding ocular side effects in cancer patients.